A positron-emission tomography (PET)/magnetic resonance imaging (MRI) platform to track <i>in vivo</i> small extracellular vesicles

Banerjee, Arnab; Alves, Vítor H.; Rondão, Tiago; Sereno, José; Neves, A. S. Campos; Lino, Miguel; Ribeiro, Andreia; Abrunhosa, Antero; Ferreira, Lino

doi:10.1039/c9nr02512j

Cited by 43 publications

(54 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Methods to track EVs in vivo and follow their biodistribution are very important to fully evaluate their cardiovascular therapeutic potential. Fluorescence 47,54,71,110,111 , luminescence 112 , positron-emission tomography (PET)/magnetic resonance imaging (MRI) 113 and single-photon emission computed tomography (SPECT) 114,115 imaging techniques have been used to monitor in vivo EVs. In most of the cases, the EVs were isolated and modified with chemical ligands 113,114 .…”

Section: 1-tracking the Evsmentioning

confidence: 99%

“…In contrast, the methods that rely in PET/MRI or SPCET/computed tomography offer higher sensitivity and absolute quantification while allowing the acquisition of images with anatomical details. In general, the intravenous administration of labelled EVs (without any further modification besides the labelling) isolated from different cell sources indicate that less than 10% of the injected EVs accumulate into the non-injured heart 54,[112][113][114][115] . Yet, the accumulation of EVs in the heart is influenced by the delivery route, concentration of EVs and the identity of the EV-secreting cell 54,[112][113][114] .…”

Section: 1-tracking the Evsmentioning

confidence: 99%

See 1 more Smart Citation

Native and bioengineered extracellular vesicles for cardiovascular therapeutics

et al. 2020

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are a heterogeneous group of natural particles with relevance for the treatment of cardiovascular diseases. The endogenous properties of these vesicles allow them to survive in the extracellular space, bypass biological barriers and deliver their biologically active molecular cargo to recipient cells. Moreover, EVs can be engineered to enhance their stability, bioactivity, presentation and capacity for on target binding at both cell type and tissue levels. The therapeutic potential of native (i.e., EVs that were not modified via donor cell or direct modulation) and engineered (i.e. EVs that were modified either pre-or post-isolation or whose pharmacokinetics/presentation was altered using engineering methodologies EVs is still limitedly explored in the context of cardiovascular diseases. Efforts to tap into the therapeutic potential of EVs will require innovative approaches and a comprehensive integration of knowledge gathered from decades of molecular compound delivery. In this review, we outline the endogenous properties of EVs that make them natural delivery agents as well as those features that can be improved using bioengineering approaches. We also discuss the therapeutic applications of native and engineered EVs for cardiovascular applications and examine the opportunities and challenges that need to be addressed to advance this research area with an emphasis on clinical translation. Key points• EVs secreted from stem/progenitor cells as well as differentiated somatic cells have regenerative properties in the context of myocardial infarction, ischemic limb, chronic wounds and stroke.

show abstract

Section: 1-tracking the Evsmentioning

confidence: 99%

Section: 1-tracking the Evsmentioning

confidence: 99%

Native and bioengineered extracellular vesicles for cardiovascular therapeutics

et al. 2020

View full text Add to dashboard Cite

show abstract

“…19 At the time of writing, there are only a handful of peer-reviewed publications on the radiolabelling and in vivo imaging of sEVs, 18,[20][21][22][23][24][25][26][27][28] of which only 3 were aimed for PET imaging using two different radioisotopes ( 64 Cu, 124 I). [26][27][28] These PET radiolabelling methods rely on the binding of these radionuclides to membrane proteins which, given the importance of these surface components in the role of sEVs as messengers and cell-cell communication, 29 may result in altered biodistribution and function. 20,28,30 Consequently, radiolabelling within the intraluminal space of sEVs is desirable.…”

Section: Introductionmentioning

confidence: 99%

[89Zr]Zr(oxinate)4 Allows Direct Radiolabelling and PET Imaging of Small Extracellular Vesicles

Khan¹,

Man²,

Faruqu³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…EV tracking can provide important knowledge, including their biodistribution, homing abilities, toxicity, biological role, and relevant mechanism of action. Multiple imaging approaches have been developed to track EVs such as BLI, FLI, MRI, PET, and CT, which can be utilized to optimize the targeting of EVs in the treatment of CNS diseases (Table 2; Banerjee et al, 2019; Betzer et al, 2017; Perets et al, 2019; van der Vos et al, 2016; Webb, Kaiser, Jurgielewicz, et al, 2018; Zhu et al, 2018).…”

Section: Imaging As a Methods To Evaluate New Classes Of Therapeutic Amentioning

confidence: 99%

Imaging as a tool to accelerate the translation of extracellular vesicle‐based therapies for central nervous system diseases

Gao

Chu

Jabłońska

et al. 2020

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are natural and diverse lipid bilayer‐enclosed particles originating from various cellular components and containing an abundance of cargoes. Due to their unique properties, EVs have gained considerable interest as therapeutic agents for a variety of diseases, including central nervous system (CNS) disorders. Their therapeutic value depends on cell origin but can be further enhanced by enrichment of cargo when used as drug carriers. Therefore, there has been significant effort directed toward introducing them to clinical practice. However, it is essential to avoid the failures we have seen with whole‐cell therapy, in particular for the treatment of the CNS. Successful launching of clinical studies is contingent upon the understanding of the biodistribution of EVs, including their uptake and clearance from organs and specific homing into the region of interest. A multitude of noninvasive imaging methods has been explored in vitro to investigate the spatio‐temporal dynamics of EVs administered in vivo. However, only a few studies have been performed to track the delivery of EVs, especially delivery to the brain, which is the most therapeutically challenging organ. We focus here on the use of advanced imaging techniques as an essential tool to facilitate the acceleration of clinical translation of EV‐based therapeutics, especially in the CNS arena. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease Diagnostic Tools > in vivo Nanodiagnostics and Imaging

show abstract

A positron-emission tomography (PET)/magnetic resonance imaging (MRI) platform to track in vivo small extracellular vesicles

Cited by 43 publications

References 41 publications

Native and bioengineered extracellular vesicles for cardiovascular therapeutics

Native and bioengineered extracellular vesicles for cardiovascular therapeutics

[89Zr]Zr(oxinate)4 Allows Direct Radiolabelling and PET Imaging of Small Extracellular Vesicles

Imaging as a tool to accelerate the translation of extracellular vesicle‐based therapies for central nervous system diseases

Contact Info

Product

Resources

About